Chiang-Ting Chou1,2, Yue-Ju Li3, Cheng-Chi Chang3,4,5, Cheng-Ning Yang4,6, Pei-Shan Li4,7, Yung-Ming Jeng8, Szu-Ta Chen9, Min-Liang Kuo10, I-Ching Lin11,12,13, Been-Ren Lin14,15. 1. Department of Nursing, Division of Basic Medical Sciences, Chang Gung University of Science and Technology, Chiayi, Taiwan. 2. Chronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Chiayi, Taiwan. 3. Department of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. 4. Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan. 5. Angiogenesis Research Center, National Taiwan University, Taipei, Taiwan. 6. Department of Otolaryngology National Taiwan University Hospital College of Medicine, National Taiwan University, Taipei, Taiwan. 7. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. 8. Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. 9. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. 10. College of Science, National Taiwan University, Taipei, Taiwan. 11. Department of Family Medicine, Changhua Christian Hospital, Taipei, Taiwan. 12. Faculty of Medicine, Chung Shan Medical University, Taipei, Taiwan. 13. Faculty of Medicine, Kaohsiung Medical University, Taipei, Taiwan. 14. Angiogenesis Research Center, National Taiwan University, Taipei, Taiwan. dtsurg92@yahoo.com.tw. 15. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. dtsurg92@yahoo.com.tw.
Abstract
BACKGROUND: To assess the correlations and functions of complement C1r/C1s, Uegf, Bmp1 domain-containing protein-1 (CDCP1) in identifying colorectal cancer (CRC) patients who are at high risk for metastasis. METHODS: Tumor specimens from 101 patients were analyzed by real-time polymerase chain reaction to detect CDCP1 expression. CDCP1 expression plasmids and shRNA were used to knock down CDCP1 expression in this study to investigate migratory and invasive abilities by Boyden chambers. The mRNA expression profiles in shCDCP1 transfectants were compared to those in control cells by conducting microarray analysis. Its downstream effectors were also invested in this study. RESULTS: CRC patients with a high CDCP1 expression had a statistically significant lower overall survival and disease-free survival compared to those exhibiting low CDCP1 expression. In vitro, knock-down CDCP1 expression significantly decreased migratory and invasive abilities in HCT116. Aberrant expression of CDCP1 increased cancer cell migration and invasion. By using integrated genomics, we identified ROCK1 (rho-associated, coiled-coil-containing protein kinase 1 pseudogene 1) as a downstream effector in CDCP1-mediated migration and as an invasion mediator. Clinically, ROCK1 and CDCP1 mRNA expression exhibited a strong positive correlation in CRC patient samples. CONCLUSIONS: Our results implicated CDCP1 as a key regulator of CRC migration and invasion, and suggest that it is a useful prognostic factor for patients with CRC. Improved identification of a high-risk subset of early metastatic patients may guide indications of individualized treatment in clinical practice.
BACKGROUND: To assess the correlations and functions of complement C1r/C1s, Uegf, Bmp1 domain-containing protein-1 (CDCP1) in identifying colorectal cancer (CRC) patients who are at high risk for metastasis. METHODS: Tumor specimens from 101 patients were analyzed by real-time polymerase chain reaction to detect CDCP1 expression. CDCP1 expression plasmids and shRNA were used to knock down CDCP1 expression in this study to investigate migratory and invasive abilities by Boyden chambers. The mRNA expression profiles in shCDCP1 transfectants were compared to those in control cells by conducting microarray analysis. Its downstream effectors were also invested in this study. RESULTS: CRC patients with a high CDCP1 expression had a statistically significant lower overall survival and disease-free survival compared to those exhibiting low CDCP1 expression. In vitro, knock-down CDCP1 expression significantly decreased migratory and invasive abilities in HCT116. Aberrant expression of CDCP1 increased cancer cell migration and invasion. By using integrated genomics, we identified ROCK1 (rho-associated, coiled-coil-containing protein kinase 1 pseudogene 1) as a downstream effector in CDCP1-mediated migration and as an invasion mediator. Clinically, ROCK1 and CDCP1 mRNA expression exhibited a strong positive correlation in CRC patient samples. CONCLUSIONS: Our results implicated CDCP1 as a key regulator of CRC migration and invasion, and suggest that it is a useful prognostic factor for patients with CRC. Improved identification of a high-risk subset of early metastatic patients may guide indications of individualized treatment in clinical practice.
Authors: Anna Moroz; Yung-Hua Wang; Jeremy M Sharib; Junnian Wei; Ning Zhao; Yangjie Huang; Zhuo Chen; Alexander J Martinko; Jie Zhuo; Shion A Lim; Lydia H Zhang; Youngho Seo; Sean Carlin; Kevin K Leung; Eric A Collisson; Kimberly S Kirkwood; James A Wells; Michael J Evans Journal: Clin Cancer Res Date: 2020-04-27 Impact factor: 12.531
Authors: Yaowu He; Claire M Davies; Brittney S Harrington; Linh Hellmers; Yonghua Sheng; Amy Broomfield; Thomas McGann; Kate Bastick; Laurie Zhong; Andy Wu; Grace Maresh; Shannon McChesney; Kuan Yau Wong; Mark N Adams; Ryan C Sullivan; James S Palmer; Lez J Burke; Adam D Ewing; Xin Zhang; David Margolin; Li Li; Rohan Lourie; Admire Matsika; Bhuvana Srinivasan; Michael A McGuckin; John W Lumley; John D Hooper Journal: Oncogene Date: 2019-08-30 Impact factor: 9.867
Authors: M Perego; M Maurer; J X Wang; S Shaffer; A C Müller; K Parapatics; L Li; D Hristova; S Shin; F Keeney; S Liu; X Xu; A Raj; J K Jensen; K L Bennett; S N Wagner; R Somasundaram; M Herlyn Journal: Oncogene Date: 2017-09-18 Impact factor: 9.867
Authors: Tahleesa J Cuda; Yaowu He; Thomas Kryza; Tashbib Khan; Brian W Tse; Kamil A Sokolowski; Cheng Liu; Nicholas Lyons; Madeline Gough; Cameron E Snell; David K Wyld; Stephen Rose; Andrew D Riddell; Andrew R L Stevenson; Paul A Thomas; David A Clark; Simon Puttick; John D Hooper Journal: Contrast Media Mol Imaging Date: 2021-09-13 Impact factor: 3.161
Authors: Lifang Yang; Sucharita M Dutta; Dean A Troyer; Jefferson B Lin; Raymond A Lance; Julius O Nyalwidhe; Richard R Drake; O John Semmes Journal: Oncotarget Date: 2015-12-22